1. 3) Katori M and Majima M: Cycloxygenase-2: its rich diversity of roles and possible application of its selective inhibitors. Inflamm Res 49, 367-392 (2000)
2. 4) Nakamura H: Neuroendocrine interactions with interleukin-1 in inflammation. In Interleukin-1, Inflammation and Disease, Edited by Bomford R and Henderson B, pp 229-241, Elsevier, Oxford (1989)
3. 6) Chan CC, Boyce S, Brideau C, Charleson S, Cromlish W, Ethier D, Evans J, Ford-Hutchinson AW, Forrest MJ, Gauthier JY, et al: Rofecoxib [Vioxx, MK-0966; 4-(4’-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles. J Pharmacol Exp Ther 290, 551-560 (1999)
4. 7) Brideau C, Kargman S, Liu S, Dallob AL, Ehrich EW, Rodger IW and Chan CC: A human whole blood assay for clinical evaluation of biochemical efficacy of cyclooxygenase inhibitors. Inflamm Res 45, 68-74 (1996)
5. 8) Penning TD, Talley JJ, Bertenshaw SR, Carter JS, Collins PW, Docter S, Graneto MJ, Lee LF, Malecha JW, Miyashiro JM, et al: Synthesis and biological evaluation of the 1,5-diarylpyrazole calss of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl] benzenesulfonamide (SC-58635, Celecoxib). J Med Chem 40, 1347-1365 (1997)